antibody_engineering_3

Antibody-drug conjugates unite precision with potency. Biointron outlines how ADCs combine antibodies with cytotoxic drugs to deliver targeted cancer therapies.

Learn about Fab, F(ab')2, and Fc antibody fragments—how they are generated, their roles in antigen targeting, and their evolving applications in biomedical research and therapy.

Bispecific antibodies are transforming medicine. Biointron highlights their design, therapeutic applications, and development pathways for next-generation therapies.

Image credit: DOI: 10.3390/cancers16040800 In recent decades, the landscape of therapeutic antibodies has undergone a rapid evolution, catalyzing breakthroughs in modern medicine. These antibodies, characterized by their precise targeting and minimal side effects

In the realm of combating bacterial infections and antimicrobial resistance, antibodies are beginning to stand out as a therapy with innovative strategies and engineering methods continually being published. This month’s trend will focus on the developments in ‘antibiotic antibodies’, antibody-antibiotic conjugates, and antibody antimicrobials, which are particularly important for immunocompromised patients.

Agonistic antibodies bind to specific receptors on cells and mimic the action of the natural ligand of that receptor, thereby activating signaling pathways and eliciting cellular responses. Unlike traditional antibodies, which are often used to block or neutralize the activity of their target molecules (acting as antagonists), antibody agonists actively stimulate a biological response. Recently, more studies are delving into the mechanisms and therapeutic potential of these antibody agonists.

Single-chain variable fragments (scFvs) combine small size with strong binding. Biointron highlights their history, uses in diagnostics and therapy, and production expertise.

Entering into the new year, the popularity of antibody-drug conjugates (ADCs) in the biopharma industry shows no signs of slowing down. In 2023, there were a record number of licensing partnerships in the ADC space, particularly Merck’s $22 billion deal with Daiichi Sankyo, Inc.

Discover advancements in antibody engineering, from bispecific formats to Fc optimization and humanization, driving innovation in next-generation therapeutic antibody development.